Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Expenses (2016 - 2026)

Summit Therapeutics filings provide 13 years of Operating Expenses readings, the most recent being $195.2 million for Q1 2026.

  • Quarterly Operating Expenses rose 192.01% to $195.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Mar 2026, up 388.22% year-over-year, with the annual reading at $1.1 billion for FY2025, 384.26% up from the prior year.
  • Operating Expenses hit $195.2 million in Q1 2026 for Summit Therapeutics, down from $224.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $568.4 million in Q2 2025 and bottomed at $15.8 million in Q2 2023.
  • Average Operating Expenses over 5 years is $130.1 million, with a median of $58.4 million recorded in 2024.
  • The largest annual shift saw Operating Expenses surged 1875.89% in 2023 before it tumbled 92.12% in 2024.
  • Summit Therapeutics' Operating Expenses stood at $21.4 million in 2022, then skyrocketed by 65.12% to $35.4 million in 2023, then skyrocketed by 85.41% to $65.6 million in 2024, then skyrocketed by 242.8% to $224.9 million in 2025, then fell by 13.21% to $195.2 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Operating Expenses are $195.2 million (Q1 2026), $224.9 million (Q4 2025), and $234.2 million (Q3 2025).